C
China Resources Pharmaceutical Group Ltd
HKEX:3320
China Resources Pharmaceutical Group Ltd
HKEX:3320
Price:
5.56
HKD
1.09%
Market Closed
Market Cap:
34.9B
HKD
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
China Resources Pharmaceutical Group Ltd
5.56
+0.06 (+1.09%)
| 52 Week Range |
4.51
6.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
China Resources Pharmaceutical Group Ltd
Balance Sheet
Balance Sheet Decomposition
China Resources Pharmaceutical Group Ltd
China Resources Pharmaceutical Group Ltd
| Current Assets | 197.6B |
| Cash & Short-Term Investments | 62B |
| Receivables | 85.6B |
| Other Current Assets | 50B |
| Non-Current Assets | 68.8B |
| Long-Term Investments | 8.6B |
| PP&E | 24.8B |
| Intangibles | 29.3B |
| Other Non-Current Assets | 6.1B |
| Current Liabilities | 144B |
| Accounts Payable | 141.9B |
| Accrued Liabilities | 3.7B |
| Other Current Liabilities | -1.6B |
| Non-Current Liabilities | 74B |
| Long-Term Debt | 21.7B |
| Other Non-Current Liabilities | 52.3B |
Balance Sheet
China Resources Pharmaceutical Group Ltd
China Resources Pharmaceutical Group Ltd
Currency: HKD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
13 418
|
12 379
|
13 960
|
14 162
|
16 633
|
12 524
|
11 231
|
17 513
|
17 043
|
24 651
|
|
| Cash |
13 418
|
12 379
|
13 960
|
14 162
|
16 633
|
12 524
|
11 231
|
17 513
|
17 043
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
24 651
|
|
| Short-Term Investments |
5 580
|
6 310
|
3 649
|
6 557
|
28 024
|
26 403
|
34 614
|
36 276
|
31 299
|
34 616
|
|
| Total Receivables |
43 847
|
45 451
|
52 773
|
64 448
|
53 880
|
63 402
|
66 447
|
69 430
|
67 872
|
75 572
|
|
| Accounts Receivables |
32 524
|
35 863
|
42 168
|
50 162
|
44 699
|
52 108
|
58 384
|
59 985
|
59 744
|
67 666
|
|
| Other Receivables |
11 324
|
9 588
|
10 605
|
14 286
|
9 181
|
11 294
|
8 062
|
9 445
|
8 128
|
7 906
|
|
| Inventory |
15 711
|
15 252
|
18 859
|
21 406
|
21 528
|
22 332
|
24 585
|
26 756
|
26 547
|
31 875
|
|
| Other Current Assets |
5 720
|
9 465
|
4 561
|
6 626
|
7 201
|
8 281
|
10 232
|
10 921
|
11 319
|
11 854
|
|
| Total Current Assets |
84 277
|
88 857
|
93 802
|
113 199
|
127 266
|
132 943
|
147 109
|
159 166
|
152 259
|
178 568
|
|
| PP&E Net |
13 506
|
13 081
|
12 766
|
15 012
|
14 930
|
22 105
|
22 890
|
23 010
|
22 092
|
25 376
|
|
| PP&E Gross |
13 506
|
13 081
|
12 766
|
15 012
|
14 930
|
22 105
|
22 890
|
23 010
|
22 092
|
25 376
|
|
| Accumulated Depreciation |
3 876
|
4 243
|
4 623
|
5 898
|
6 143
|
6 890
|
8 315
|
8 965
|
9 594
|
11 136
|
|
| Intangible Assets |
3 431
|
3 948
|
3 813
|
4 755
|
4 981
|
6 093
|
6 967
|
8 230
|
7 592
|
8 040
|
|
| Goodwill |
15 322
|
16 395
|
17 405
|
20 545
|
19 805
|
19 306
|
21 072
|
22 442
|
20 409
|
21 454
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1 018
|
790
|
|
| Long-Term Investments |
1 799
|
1 610
|
3 462
|
3 948
|
5 076
|
6 969
|
8 270
|
8 767
|
8 114
|
10 648
|
|
| Other Long-Term Assets |
3 464
|
3 259
|
2 736
|
3 296
|
4 126
|
2 610
|
3 063
|
2 396
|
4 049
|
1 894
|
|
| Other Assets |
15 322
|
16 395
|
17 405
|
20 545
|
19 805
|
19 306
|
21 072
|
22 442
|
20 409
|
21 454
|
|
| Total Assets |
121 798
N/A
|
127 149
+4%
|
133 986
+5%
|
160 754
+20%
|
176 184
+10%
|
190 025
+8%
|
209 372
+10%
|
224 013
+7%
|
215 534
-4%
|
246 770
+14%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
30 857
|
33 436
|
39 851
|
42 217
|
39 526
|
42 747
|
45 697
|
108 971
|
118 219
|
133 656
|
|
| Accrued Liabilities |
1 666
|
1 722
|
2 058
|
2 452
|
3 219
|
2 674
|
3 174
|
3 505
|
3 963
|
4 231
|
|
| Short-Term Debt |
302
|
482
|
0
|
0
|
3 424
|
0
|
0
|
0
|
9 805
|
2 991
|
|
| Current Portion of Long-Term Debt |
20 351
|
24 335
|
19 327
|
33 432
|
37 363
|
30 389
|
40 992
|
43 651
|
36 799
|
46 224
|
|
| Other Current Liabilities |
12 298
|
12 248
|
9 750
|
13 633
|
19 827
|
30 862
|
32 756
|
33 001
|
22 349
|
26 206
|
|
| Total Current Liabilities |
65 472
|
72 224
|
70 985
|
91 734
|
103 358
|
106 672
|
122 620
|
127 365
|
121 770
|
134 233
|
|
| Long-Term Debt |
16 912
|
12 883
|
6 385
|
3 444
|
10 150
|
10 876
|
3 164
|
7 312
|
9 812
|
15 937
|
|
| Deferred Income Tax |
816
|
862
|
938
|
964
|
881
|
1 507
|
1 669
|
1 771
|
1 587
|
1 718
|
|
| Minority Interest |
16 634
|
17 343
|
16 682
|
21 267
|
21 156
|
28 870
|
33 560
|
39 657
|
37 000
|
47 015
|
|
| Other Liabilities |
1 447
|
1 334
|
1 376
|
1 474
|
1 326
|
1 389
|
1 890
|
1 962
|
1 807
|
1 907
|
|
| Total Liabilities |
101 281
N/A
|
104 646
+3%
|
96 365
-8%
|
118 884
+23%
|
136 871
+15%
|
149 314
+9%
|
162 902
+9%
|
178 066
+9%
|
171 977
-3%
|
200 811
+17%
|
|
| Equity | |||||||||||
| Common Stock |
12 474
|
12 474
|
27 241
|
27 241
|
27 241
|
27 241
|
27 241
|
24 551
|
24 630
|
24 630
|
|
| Retained Earnings |
7 043
|
10 205
|
11 845
|
13 476
|
13 392
|
15 629
|
18 211
|
19 208
|
20 839
|
23 314
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Unrealized Security Profit/Loss |
0
|
2
|
174
|
195
|
226
|
428
|
486
|
453
|
491
|
606
|
|
| Other Equity |
1 000
|
178
|
1 640
|
958
|
1 546
|
2 587
|
531
|
1 734
|
2 404
|
2 591
|
|
| Total Equity |
20 516
N/A
|
22 502
+10%
|
37 620
+67%
|
41 870
+11%
|
39 313
-6%
|
40 711
+4%
|
46 470
+14%
|
45 946
-1%
|
43 557
-5%
|
45 960
+6%
|
|
| Total Liabilities & Equity |
121 798
N/A
|
127 149
+4%
|
133 986
+5%
|
160 754
+20%
|
176 184
+10%
|
190 025
+8%
|
209 372
+10%
|
224 013
+7%
|
215 534
-4%
|
246 770
+14%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
4 629
|
4 629
|
6 285
|
6 285
|
6 285
|
6 285
|
6 283
|
6 283
|
6 283
|
6 283
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
